Veterinary Chewable Base Excipients Market Report 2026

The veterinary chewable base excipients market size has grown strongly in recent years. It will grow from $1.53 billion in 2025 to $1.63 billion in 2026 at a compound annual growth rate (CAGR) of 6.9%. The growth in the historic period can be attributed to low medication adherence in animals due to poor palatability, reliance on traditional tablet and injectable veterinary dosage forms, limited availability of species specific flavored drug formulations, growing demand for improved veterinary treatment compliance, increasing use of basic sugar and gelatin based excipients in formulations.

The veterinary chewable base excipients market size is expected to see strong growth in the next few years. It will grow to $2.15 billion by 2030 at a compound annual growth rate (CAGR) of 7.1%. The growth in the forecast period can be attributed to integration of ai driven formulation design and palatability prediction tools, expansion of personalized veterinary medicine requiring tailored excipient systems, growing adoption of biodegradable and sustainable excipient materials, increasing investment in advanced drug delivery systems for animals, rising demand for precision dosing and enhanced compliance driven formulations. Major trends in the forecast period include ai driven palatability optimization and formulation analytics for veterinary excipients, smart manufacturing of chewable dosage forms using automated mixing and precision dosing systems, cloud based formulation data management and excipient quality tracking platforms, advanced flavor masking and taste enhancement technologies for improved animal medication compliance, sustainable and biodegradable excipient development for eco friendly veterinary drug formulations.

The rising pet ownership and companion animal population are expected to propel the growth of the veterinary chewable base excipients market going forward. "Pet ownership and companion animal population" refers to the number and proportion of households that own pets and the overall population of domesticated animals kept for companionship, such as dogs and cats, within a specific region. The increase in pet ownership and companion animal population is driven by the growing humanization of pets, where people increasingly consider pets as family members and spend more on their care, companionship, and overall well-being. The growing demand for pet ownership and companion animal populations increases the need for more palatable and easy-to-administer veterinary medications, thereby boosting demand for veterinary chewable base excipients used in the formulation of flavored and animal-friendly dosage forms. For instance, in March 2025, according to the American Pet Products Association, a US-based non-profit association, currently, 94 million households in the U. S. own at least one pet, representing an increase from 82 million households in 2023. Therefore, rising pet ownership and companion animal populations are driving the growth of the veterinary chewable base excipients market.

The growing prevalence of chronic and lifestyle diseases in animals is expected to propel the growth of the veterinary chewable base excipients market going forward. Chronic and lifestyle diseases in animals refer to persistent health conditions that develop due to factors such as improper nutrition, lack of exercise, aging, or environmental influences, and require continuous care and management. The increasing prevalence of chronic and lifestyle diseases in animals is driven by rising pet obesity caused by overfeeding and lower physical activity, which significantly increases the risk of long-term conditions such as diabetes and osteoarthritis. The increasing prevalence of chronic and lifestyle diseases in animals increases the demand for long-term, palatable treatment options, thereby driving demand for veterinary chewable base excipients used to formulate easy-to-administer and compliant dosage forms. For instance, in October 2024, according to Portland Vets Limited, a UK-based, family-owned, independent small animal veterinary practice, in the 2024 campaign, 45% of animals were overweight or obese, including 46% of dogs and 43% of cats. Therefore, the growing prevalence of chronic and lifestyle diseases in animals is driving the growth of the veterinary chewable base excipients market.

The expansion of veterinary healthcare infrastructure is expected to propel the growth of the veterinary chewable base excipients market going forward. Veterinary healthcare infrastructure refers to the network of clinics, hospitals, specialists, and support systems that enable the diagnosis, treatment, and prevention of diseases in animals. The increasing scale of veterinary infrastructure is mainly driven by rising pet ownership across developed nations, as more households consider pets as family members and seek regular, high-quality veterinary care, thereby increasing the demand for expanded clinical facilities and specialized services. The expansion of veterinary infrastructure increases the use of pharmaceutical formulations, including chewable dosage forms, as more animals receive routine treatments, preventive medications, and therapeutic interventions within clinical environments. For instance, in December 2023, according to data published by the American Veterinary Medical Association (AVMA), a U. S. -based non-profit organization and the leading national veterinary association in the United States, the total number of veterinarians in the U. S. increased from 124,069 in 2022 to 127,131 in 2023, reflecting a net addition of more than 3,000 professionals, indicating the steady expansion of veterinary service capacity across the country. Therefore, the expansion of veterinary healthcare infrastructure is driving the growth of the veterinary chewable base excipients market.

Major companies operating in the veterinary chewable base excipients market are Cargill Incorporated, Archer Daniels Midland Company, International Flavors & Fragrances Inc., IMCD N. V., Clariant AG, Omya AG, Roquette Frères, Croda International Plc, Ashland Inc., Kemin Industries Inc., JRS Pharma GmbH & Co. KG, SPI Pharma Inc., Gattefossé SAS, Lipoid GmbH, Lesaffre et Compagnie, Sigachi Industries Limited, Accent Microcell Private Limited, Nitika Pharmaceuticals Limited, Salius Pharma Private Limited, MEGGLE GmbH & Co. KG, AdvaCare Pharma USA LLC, Shreeji Pharma International Private Limited.

North America was the largest region in the veterinary chewable base excipients market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the veterinary chewable base excipients market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the veterinary chewable base excipients market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The veterinary chewable base excipients market consists of sales of flavoring agents, binders, fillers or diluents, sweeteners, disintegrants, lubricants, glidants, preservatives, stabilizers and coloring agents. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.